Level C· Early human research exploring benefitsCase Report / SeriesPubMed

Parosteal lipoma of the thigh with cartilaginous and osseous differentiation: an osteochondrolipoma.

Rau T., Soeder S., Olk A., Aigner T.

Case Report / Series on Cartilage Damage, published in Ann Diagn Pathol (2006) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Case Report / Series
Journal
Ann Diagn Pathol (2006)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
16979520
DOI
10.1016/j.anndiagpath.2006.03.009

Abstract (original English)

Lipomas are very common benign soft tissue neoplasms. They are usually slow-growing and may occur anywhere in the body. Mature cartilage and bone arising in a lipoma is a rare event and is mostly associated with a parosteal localization of the neoplasm. We describe a new case of osteochondrolipoma showing not only major adipocytic differentiation but also areas of fibrocytic and cartilaginous cell differentiation and bone formation (both endochondral and membranous). The occurrence of at least 4 distinct directions of mesenchymal cell differentiation within a benign neoplasia underlines the concept of multilineage differentiation of pluripotent mesenchymal stem cells. Such a multidirectional potential was recently well established in vitro in stem cells present in adult adipocytic tissue.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
AdipocytesAgedBone and BonesCartilageCell DifferentiationCell Transformation, NeoplasticDiagnosis, DifferentialHumansLipomaMale

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research